/Investor DB

Kurma Partners — 2020 Investments

6 investments dated 2020 · listed companies and verified rows first · show all

Synendossynendos.cominNov 2020✓ verified

Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders.

BiotechDeep TechDigital HealthMental HealthBasel, CH

Prof. Jürg Gertsch(Founder)Dr. Andrea Chicca(Co-Founder & Chief Executive Officer)Dr. Simon Russell(Co-Founder & Chief Commercial Officer)

Co-investorsYsios CapitalHigh Tech GruenderfondsSunstone Capital

Imcheckimchecktherapeutics.cominSeries A · Sep 2020 · $22Macquired by Clementia

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.

BiotechHealthtech

Daniel Olive(Founder)in

Co-investorsAgent CapitalAndera PartnersPfizer Venture InvestmentsPureos BioventuresAlexandriaBpifrance+4 more

Vicovico.ioin𝕏Jul 2020 · $31M

VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.

AI & Machine LearningData & InfrastructureFintech

Co-investorsAIN VenturesMultiball CapitalDroia VenturesEQT Life SciencesEurazeoPureos Bioventures

Vicogetvico.cominAug 2020 · $31M

VICO is an online platform for finding verified furnished monthly housing — rooms, studios, and apartments — aimed at students, young professionals, and digital nomads relocating to a new city.

B2B MarketplacesConsumerMarketplacesPropTechTravel & HospitalityMedellín, CO

Manuel FranzinTilman Burfeindin

Co-investors500 GlobalDroia VenturesEQT Life SciencesEurazeoPureos Bioventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Corlieve TherapeuticsLucine

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.